US 12,479,842 B2
Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease
Pierre Louis Beaulieu, Rosemère (CA); Eric Beaulieu, Mercier (CA); Joanne Tan, San Mateo, CA (US); Yannick Rose, Montréal (CA); Michael Dore, Saint-Bruno-de-Montarville (CA); Doris Schuetz, Montréal (CA); Mukund Ghavre, Saint-Laurent (CA); and Jacques Banville, Saint-Hubert (CA)
Assigned to Universite de Montreal, Montreal (CA)
Appl. No. 18/287,610
Filed by Universite de Montreal, Montréal (CA)
PCT Filed Apr. 19, 2022, PCT No. PCT/CA2022/050592
§ 371(c)(1), (2) Date Oct. 19, 2023,
PCT Pub. No. WO2022/221939, PCT Pub. Date Oct. 27, 2022.
Claims priority of provisional application 63/201,219, filed on Apr. 19, 2021.
Prior Publication US 2024/0217971 A1, Jul. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); A61K 31/675 (2006.01); A61P 35/00 (2006.01); C07D 519/00 (2006.01); C07F 9/6561 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 31/675 (2013.01); A61P 35/00 (2018.01); C07D 519/00 (2013.01); C07F 9/6561 (2013.01)] 22 Claims
 
1. A compound of formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein each R14 is, independently, selected from H, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C3-10 cycloalkyl, optionally substituted C4-10 heterocycloalkyl, optionally substituted C6 aryl, and optionally substituted C5-10 heteroaryl, or each R14 and their adjacent nitrogen atom together form an optionally substituted C4-10 heterocycloalkyl group.